Hagens Berman Advises Investors of May 13, 2014, Deadline in Geron Corporation Securities Lawsuit and Investigation

  Hagens Berman Advises Investors of May 13, 2014, Deadline in Geron
  Corporation Securities Lawsuit and Investigation

Business Wire

BERKELEY, Calif. -- March 31, 2014

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is
investigating Geron Corporation (NASDAQ: GERN) (“Geron” or “the Company”) for
securities fraud following allegations that the company distributed false and
misleading statements to investors concerning its business and prospects, and
advises investors of the class-action lead plaintiff deadline on May 13, 2014.
Investors who have suffered significant financial losses, and who want to
discuss their options, can contact a Hagens Berman attorney by emailing
Geron@hbsslaw.com.

The securities fraud class-action lawsuit, filed on March 14, 2014, on behalf
of investors who purchased Geron stock between June 16, 2013 and March 11,
2014 (the “Class Period”), alleges that the company failed to disclose key
information to its investors regarding halting of its sponsored clinical
trials by the FDA.  For more information about the suit, please contact Hagens
Berman Partner Reed Kathrein, who is leading the firm’s investigation, by
calling 510-725-3000. Additional information is available at
http://hb-securities.com/investigations/Geron.

The complaint alleges that Geron, a clinical stage biopharmaceutical company,
misrepresented or failed to disclose that persistent low-grade liver function
test (LFT) abnormalities had been observed in the study of imetelstat – the
company’s sole product candidate. According to the complaint, the company
received notice from the FDA on March 12, 2014, that its work with imetelstat
had been placed on full clinical hold, greatly affecting Geron’s sponsored
clinical trials; Geron failed to disclose this information to investors. This
hold was due to the potential risk of chronic liver injury following long-term
exposure to imetelstat. Following this news, Geron shares declined $2.71 per
share, more than 61 percent, to close at $1.69 per share on March 12, 2014.

“We believe that Geron did not adequately disclose the existence of persistent
low-grade liver function tests and the concerns this raised about their
prospects,” said Mr. Kathrein. “While Geron may have hoped that the FDA would
not take action, the company has admitted that it was sufficiently concerned
about the occurrence of these abnormalities that the company discussed the
issue with its expert panel.”

The deadline to file for lead plaintiff in a recently filed securities fraud
class action is May 13, 2014.

Persons with non-public information regarding Geron should consider their
options to help in the investigation or take advantage of the SEC
Whistleblower program. Under the new SEC Whistleblower program, whistleblowers
who provide original information may receive rewards totaling up to 30 percent
of any successful recovery made by the SEC.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm
with offices in nine cities. The Firm represents investors, whistleblowers,
workers and consumers in complex litigation. More about the law firm and its
successes can be found at www.hb-securities.com. Read the Firm’s Securities
Newsletter at http://www.hb-securities.com/newsletter. The firm’s blog is
located at www.meaningfuldisclosure.com.

Contact:

Firmani + Associates
Mark Firmani, 206-443-9357
mark@firmani.com
 
Press spacebar to pause and continue. Press esc to stop.